Intravitreal topotecan
Phase 2Small molecule
Intravitreal topotecan is one of 20 small molecule programs targeting Proliferative Vitreoretinopathy. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Proliferative Vitreoretinopathy
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsApproved
Accutane
CConrado Roberto Hoffmann Filho
Approved
Adrucil
EElorac, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Kenalog
BBausch Health Americas, Inc.
Phase 3
Trexall
Alnylam PharmaceuticalsPhase 2
Intravitreal Aflibercept
RegeneronPhase 2
ADX-2191
AAldeyra Therapeutics, Inc.
Phase 3
Rhopressa
FFalcon
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intravitreal topotecan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUnity Health Toronto